Abstract
Importance Scarce information exists concerning the seroconversion and adverse events after immunization (AEFI) of the fourth dose of a SARS-COV-2 vaccine.
Objective Correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI of the fourth dose of BNT162b2 mRNA.
Design Observational study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured 21-28 days after the exposition of the first, and second dose, three months after the second dose, 1-7 days after the third dose, before the fourth dose, and 21-28 days after the fourth dose of BNT162b2 mRNA.
Setting The study was conducted on healthcare workers of a private hospital in Northern Mexico.
Participants Inclusion criteria were healthcare workers of both genders, any age, who planned to conclude the immunization regimen. The exclusion criteria were previously given any SARS-CoV-2 vaccine prior to study entry.
Intervention Subjects were exposed to four doses of the BNT162b2 mRNA vaccine.
Main Outcome and Measures:
The anti-S1 and anti-S2 IgG antibodies against SARS-CoV-2 in plasma samples were measured with chemiluminescence immunoassay developed by DiaSorin.
Results We recruited 112 subjects [43 (SD 9) years old, 74% women].
After the first dose, subjects had a median (IQR) AU/ml IgG of 122(1904), with an increase to 1875 (2095) after the second dose, 3020 (2330) after the third dose, and 4230 (3393) after 21-28 of a fourth dose (p<0.01). The number (%) of any AEFI between doses was 90 (80.4), 89(79), 65(58), 69 (61.5), after first, second, third, and fourth, respectively, p<0.001. After the fourth dose, the most frequent AEFI was pain at the injection site (87%). Fever was slightly more frequent after the third and fourth doses, 9 (13.8) and 8 (11.4%) cases, respectively, and adenopathy was more frequent after the fourth dose [in11(15.7%) cases]. There was a correlation between AEFI in the fourth dose with gender and antibody levels (p<0.05). The highest proportion of AEFI was considered mild after the fourth dose. During the Omicron outbreak, 6 (5.3%) had mild SARS-CoV-2 during 8-28 days of the fourth dose.
Conclusions and Relevance The fourth dose of BNT162b2mRNA increases S1/S2 IgG 33.6 times with mild adverse events.
Registration number NCT05228912
Question What is the magnitude of antibody response to vaccination and adverse events after immunization (AEFI) of a fourth dose of BNT162b2 mRNA?
Findings This cohort included 112 healthcare workers. We measured S1/S2 IgG vs. SARS-CoV-2 after the first, second, third and fourth dose. Compared to the first dose, antibodies increased 33.6 times the antibody levels after the fourth dose. We found minimal to moderate adverse events. The change in antibodies correlated with AEFI. During the Omicron outbreak 6 (5.3%) had mild SARS-CoV-2.
Meaning A fourth dose of BNT162b2mRNA increases S1/S2 IgG with mild to moderate adverse events.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was conducted using private funding from Techint Group of Companies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/local Institutional Review Board from the school of Medicine from Universidad de Monterrey gave ethical approval: Ref.:26022021-CN-1e-CI. Funding
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors